Good welfare! With the Spring Festival approaching, Chongqing Zhifei Biological Products Co.Ltd(300122) (300122) issued a “big red envelope” to employees, benefiting a large number of people, which can be called rare in the A-share market.
By fully soliciting the opinions of employees and based on the confidence in the long-term development of listed companies, Chongqing Zhifei Biological Products Co.Ltd(300122) will launch an employee stock ownership plan to improve the cohesion of employees and attract and retain excellent management talents and business backbone. Chongqing Zhifei Biological Products Co.Ltd(300122) elevates the plan to a high level – that is, common prosperity, and the total number of beneficiaries is expected to reach 2000.
Recently, Chongqing Zhifei Biological Products Co.Ltd(300122) has issued an announcement on the pre increase of performance in 2021, and the net profit is expected to reach 10 billion, with a year-on-year increase of more than twice. In addition, the recombinant subunit covid-19 vaccine developed by Zhifei in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences has been certified by many authoritative experts. Vaccinators can effectively produce neutralizing antibodies against Omicron mutant.
1:1 upper limit of allocation scale: 3.2 billion yuan
On January 28, Chongqing Zhifei Biological Products Co.Ltd(300122) (300122) issued an announcement. At the board meeting held on the same day, the draft employee stock ownership plan for common prosperity (2022) was considered and adopted. The total amount of funds raised in this plan is no more than 1.6 billion yuan, and the total share of the plan is no more than 1.6 billion yuan.
In particular, the Chongqing Zhifei Biological Products Co.Ltd(300122) employee stock ownership plan stipulates that the total number of participants shall not exceed 2000.
Among them, 14 directors, supervisors and senior staff participated in the ESOP, with a total subscription share of no more than 542 million, accounting for no more than 33.88% of the total share of the ESOP; The total subscription share of other employees shall not exceed 1.058 billion, accounting for no more than 66.13% of the total share of the employee stock ownership plan; After subscribing for the plan shares, the participants of the employee stock ownership plan will become the share holders of the plan, and the source of funds is their legal salary, self raised funds and other ways permitted by laws and administrative regulations.
Further, after the establishment of the Chongqing Zhifei Biological Products Co.Ltd(300122) employee stock ownership plan, it will entrust trust plans, asset management plans, private equity funds and other professional institutions with management qualifications to manage it. It is planned to realize that the proportion of financing amount to self raised amount will not exceed 1:1 through the methods allowed by laws and regulations, and the upper limit of the scale of management organization products is 3.2 billion yuan.
It is planned to acquire shares through secondary market purchase (including but not limited to centralized bidding, block trading) and other ways permitted by laws and regulations. If the upper scale limit of the management organization’s products is 3.2 billion yuan and the closing price of Chongqing Zhifei Biological Products Co.Ltd(300122) on January 28, 2022 is 105.62 yuan / share, the subject shares that the management organization’s products can purchase and hold are about 30297300 shares, Accounting for about 1.89% of the total share capital of Chongqing Zhifei Biological Products Co.Ltd(300122) , the final number of shares held shall be subject to the actual implementation, and the upper limit is that the total number of shares shall not exceed 10% of the total share capital of the listed company.
The draft points out that the duration of the employee stock ownership plan is 48 months, which can be extended from the date when the general meeting of shareholders deliberates and approves the employee stock ownership plan and the subscription of the employee stock ownership plan; When the lock-in period of the underlying shares involved in the employee stock ownership plan expires and the assets of the employee stock ownership plan are monetary funds, the employee stock ownership plan can be terminated in advance with the consent of the Management Committee; The lock-in period of the employee stock ownership plan is 12 months, calculated from the time when Chongqing Zhifei Biological Products Co.Ltd(300122) announces the last transfer of the underlying stock.
On January 24, Chongqing Zhifei Biological Products Co.Ltd(300122) has announced that the net profit in 2021 is expected to be 9.9 billion yuan ~ 10.56 billion yuan, with a year-on-year increase of 200% ~ 220%. In addition, the freeze-dried human rabies vaccine (MRC-5 cells) developed by Anhui zhifeilong Kema biopharmaceutical Co., Ltd. (hereinafter referred to as zhifeilong Kema), a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co.Ltd(300122) , has obtained the summary report of phase III clinical trial.
Zhifei covid-19 vaccine can have an effect on Omicron
Recently, the international top academic journal New England Journal of Medicine published a research paper online, indicating that zf2001 (zhikeweide) vaccinators can effectively produce neutralizing antibodies against Omicron mutant.
According to the above research, the immune escape of Omicron mutant was serious, and only 6.25% of the recovered patients were positive.
However, zf2001 vaccine, with an interval of more than 3 months between two or three injections, can produce 100% neutralizing antibody against Omicron mutant, and the neutralization titer of Omicron mutant is only 3.1 times lower than that of the prototype strain. The serum of the immune program also has a good neutralization effect on alpha, beta, Delta and other mutant strains. The neutralization titer for the prototype strain is 1599, the neutralization titer for delta is 2133, and the neutralization titer for Omicron mutant strain is still 516.
The above results show that zf2001 recombinant subunit vaccine can still produce very good neutralization effect on Omicron mutant with serious immune escape. In addition, after multiple immunization and optimization of immunization strategy, the cross neutralization effect of zf2001 vaccine on mutant strains is significantly improved, which has very good potential for cross protection of mutant strains and establishment of immune barrier in the future.
In addition, academician Xie Xiaoliang and Professor Zhang Wenhong recently published a document in cell research, which also showed that zf2001 recombinant subunit vaccine, as a reinforcing needle of inactivated vaccine, is safe and effective, and can produce higher neutralizing antibody. The results of Zhang Wenhong’s research in “new pathogens and infection” show that zf2001 recombinant subunit vaccine, as the booster needle of inactivated vaccine, also has higher neutralizing antibody titer against Omicron mutant, which is a good candidate booster needle.
According to the data, zf2001 was jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and zhifeilong Kema. The results of the international multicenter phase III clinical trial have shown that the protective efficacy of the vaccine against covid-19 of any severity is 81.43%, meeting the effectiveness standard of covid-19 vaccine required by who. Preliminary genotyping analysis showed that the protective efficacy of zf2001 vaccine against alpha variant was 92.68%, and that against delta variant was 81.38%.
In January 11th, the official WeChat official account of Chongqing Zhifei Biological Products Co.Ltd(300122) revealed that the Indonesia Drug Administration (BPOM) held a press conference. The New Coronavirus vaccine (CHO cell) (Zifivax) was approved as a sequential (heterologous) booster for COVID-19 inactivated vaccine.
It is reported that penny K Lukito pointed out that as the basic immunization, zifivax vaccine was inoculated with two sequential (heterologous) booster shots of covid-19 inactivated vaccine. After 6 months of inactivated vaccine, one dose of zifivax vaccine could increase the level of neutralizing antibody by about 30 times. On January 22, Chongqing Zhifei Biological Products Co.Ltd(300122) received the document on the emergency use license of zifivax in Colombia, and officially granted the emergency use license of the vaccine according to the resolution of Colombia’s State Food and drug administration.
